Differentiation and definition of vascular-targeted therapies. - Wikidata - awgldk - TriplyDB

Differentiation and definition of vascular-targeted therapies.

Differentiation and definition of vascular-targeted therapies.

http://www.wikidata.org/entity/Q36035268

about

Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.The impact of hypoxia and its modification of the outcome of radiotherapy Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor Modalities Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics.An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503 Selective targeting of liver cancer with the endothelial marker CD146.Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.Cardiovascular toxicity profiles of vascular-disrupting agents.Targeting the tumor vascular supply with vascular disrupting agents Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.Vascular development in mouse lung metastases.The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.Vascular disrupting agents in clinical development Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.Vascular targeted therapies in oncology.

P2860

Q24651349-E4AE173A-1063-49DC-8062-7135A58C1F03 Q26779537-D79F152C-C41C-405B-9201-286D9CAF3961 Q28268126-7A75D01E-F36D-41EC-9DAD-CC5F3F5A06BD Q28397132-8A93BC82-1E1A-49C7-B25E-E959D03279EA Q28397726-9F6B058A-EE6B-4F33-98B8-147C4FB42755 Q28488869-E6861ADB-A2E9-4A88-9924-3BB2B4273414 Q28508687-4BF74D87-1F62-4598-9402-88203122DB68 Q28543671-9EFAB37C-C1AF-4E34-B5C9-76ECC7C924B6 Q33159659-A45438F3-D5B6-4EF6-B159-9202F1A10A22 Q33286035-B6419BA8-B4D9-4545-A4F5-0EDBFA3F8A8C Q33664307-51C4D2EA-C626-47C7-922E-E2D98E9A1226 Q33715830-5639F011-443A-4074-8456-E9D7560237E0 Q33738607-E4D05169-06E6-4BC7-9DBE-354EA8F0D2AA Q33843943-075E13E5-20C4-403C-A8FB-B3D2C59CB3A5 Q34093032-6C3DD8A6-BD23-4A97-9797-2BDAB0C8FF74 Q34122191-C1E38EE8-8349-4D27-8462-446D7A3C2BBF Q34155028-82BA0448-E604-49B9-BBFE-1259D51048E4 Q34296779-8962F814-A835-4D95-8F79-E62F457869C1 Q34483695-84305C4E-AF9F-46E2-8B79-51ED8F134B7C Q34491366-3A69D037-123A-43BC-BF94-B3669043ED0E Q34547313-29A006D9-2A21-4331-BE05-7241459BC196 Q34694874-7918B1BD-2395-4381-8484-F2C8BC54BAFA Q34765364-41E4ED37-A3DE-4ECE-86E8-DACF1784C263 Q35570450-2AD348DE-DA04-46D5-AFC1-69C66E2AFDD6 Q35584746-7C77600D-D08B-4EEE-89C1-4357883D7432 Q35667726-ACC839D3-CCE1-45B3-BAED-F2B78DE0DBFD Q35667802-B05FF425-B840-4F96-87C0-B1A75C221D2E Q35743971-F0717C77-1CBF-47B9-AE7C-9772A17A929A Q36206495-CE9DCAB1-6AE0-4372-99A9-2F1C6C5C19BC Q36213741-E4E95410-82F4-4C00-B26F-6D39BBF87829 Q36270034-44548016-A258-44B5-A2DD-51EF73E9F357 Q36433061-5D4844EA-9EB4-4AEF-9123-22143A1E9E6D Q36756648-F2BF6B44-ED26-42FA-826A-5C719F655447 Q36765436-4178E970-8215-435D-97A2-FF57CD52E4EC Q36788673-6FC99163-9A9E-4F2E-8A2E-75E876FC33FB Q36929601-34CB1680-E3EF-4F20-BC9A-C432A7106D85 Q36943978-82D77599-1698-4C74-AA2E-4B53B1149D4F Q36968457-EBFE52CC-EDD6-470C-BFB0-4439529596B7 Q37130150-ED187BB3-04A6-46E2-B54A-4CE1DD89D65A Q37254370-2D2A17C3-6CAB-4A6F-87E5-241A80CF3E6B

P2860

Differentiation and definition of vascular-targeted therapies.

http://www.wikidata.org/entity/Q36035268

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Differentiation and definition of vascular-targeted therapies.

@ast

Differentiation and definition of vascular-targeted therapies.

@en

type

label

Differentiation and definition of vascular-targeted therapies.

@ast

Differentiation and definition of vascular-targeted therapies.

@en

prefLabel

Differentiation and definition of vascular-targeted therapies.

@ast

Differentiation and definition of vascular-targeted therapies.

@en

P1433

Q36035268-2FCED00A-A316-4517-8EC6-AC0949FEE493

P1476

Q36035268-6415CBD7-2DDD-48BF-BD9E-F30FDA53A792

P2093

Q36035268-05936362-8114-4859-804A-119656BBA6B7

Q36035268-483DBEDE-D1BE-4757-98B6-487431484DE4

Q36035268-8E499184-7191-4B05-98DC-B8FFF79748DA

Q36035268-9B426E31-DBF6-4893-B846-E9A2F0AC3AEE

Q36035268-CC42A8DA-117F-4941-A395-5B53A60133A7

Q36035268-E7D3DBD2-BDB3-4428-8E54-698045407BA3

Q36035268-EB0D2234-3E13-431C-A16E-0DBC7D7227C3

Q36035268-F15AA601-7808-47DF-BDAA-18A9B12A31C9

P304

Q36035268-FB75BD7D-C612-4A01-9C38-CF1E600BF6A3

P31

Q36035268-7B17EF00-44C7-4413-8774-556E8B239132

P407

Q36035268-A4DBD673-0448-450B-B4F6-17645F9252B8

P433

Q36035268-6E30287F-E778-4DA1-9C85-B3D14B8A8BA4

P478

Q36035268-45EBCA34-3DF3-46A9-8D1D-8B4062CA8C40

P577

Q36035268-1A7E613A-5DF3-4165-8972-C2A288DB02A7

P698

Q36035268-DA9C0658-2164-4232-AD44-6C805271CE94

P1433

Clinical Cancer Research

P1476

Differentiation and definition of vascular-targeted therapies

@en

P2093

Adam P Dicker

http://www.w3.org/2001/XMLSchema#string

Dieter Marmé

http://www.w3.org/2001/XMLSchema#string

Dietmar W Siemann

http://www.w3.org/2001/XMLSchema#string

Ferry A L M Eskens

http://www.w3.org/2001/XMLSchema#string

Graham G Dark

http://www.w3.org/2001/XMLSchema#string

Michael C Bibby

http://www.w3.org/2001/XMLSchema#string

Michael R Horsman

http://www.w3.org/2001/XMLSchema#string

Patricia M Lorusso

http://www.w3.org/2001/XMLSchema#string

P304

416-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

2 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15701823

http://www.w3.org/2001/XMLSchema#string